Cargando…
Post-allogeneic stem cell transplant FLT3- targeted maintenance therapy: updates and considerations for clinical practice
Acute myeloid leukemia (AML) is characterized by multiple molecular and cytogenetic abnormalities, with increasing data to support clinical and prognostic implications to guide clinical decision making. One of the most well described mutations involves fms-like tyrosine kinase 3 (FLT3) that results...
Autores principales: | Cohen, Jonathan, Maziarz, Richard T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802584/ https://www.ncbi.nlm.nih.gov/pubmed/36594901 http://dx.doi.org/10.46439/stemcell.3.015 |
Ejemplares similares
-
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
por: Blackmon, Amanda, et al.
Publicado: (2022) -
FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta‐analysis
por: Fei, Xinhong, et al.
Publicado: (2022) -
P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA
por: Žučenka, Andrius, et al.
Publicado: (2023) -
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
por: Maziarz, Richard T., et al.
Publicado: (2020) -
The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant
por: Li, Grace Xiuqing, et al.
Publicado: (2018)